Amiodarone-Induced Pulmonary Toxicity - A Frequently Missed Complication. by Sweidan, Alexander J et al.
UC Irvine
UC Irvine Previously Published Works
Title
Amiodarone-Induced Pulmonary Toxicity - A Frequently Missed Complication.
Permalink
https://escholarship.org/uc/item/7w90g4g0
Authors
Sweidan, Alexander J
Singh, Navneet K
Dang, Natasha
et al.
Publication Date
2016
DOI
10.4137/ccrep.s39809
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
91CliniCal MediCine insights: Case RepoRts 2016:9
Introduction
Amiodarone is often used in the suppression of tachyar-
rhythmias.1 One of the more serious adverse effects includes 
amiodarone pulmonary toxicity (APT).1 Several pulmonary 
diseases can manifest, including interstitial pneumonitis, 
organizing pneumonia, acute respiratory distress syndrome, 
diffuse alveolar hemorrhage, pulmonary nodules or masses, 
and pleural effusion.1 The incidence of APT varies from 5% to 
15% and is correlated with dosage, age of the patient, and pre-
existing lung disease.2–4 In this report, we describe a patient, 
who received a home dose of amiodarone, presented with APT 
status post coronary artery bypass graft (CABG). The patient 
has given consent for publication of this report.
Case Report
A 56-year-old male with a medical history of coronary artery 
disease, multivessel disease, and chronic obstructive pulmo-
nary disease (COPD) was admitted for a CABG. Of note, 
the patient continued to receive his home dose of amiodarone 
400 mg orally twice daily, which he had been taking for the 
past three months for treatment of ventricular tachycardia. 
On postoperative day 1, he became hypoxemic and a chest 
X-ray (CXR) was obtained, demonstrating bilateral infiltrates. 
He reported feeling weak, dyspneic at rest, and warmer than 
normal. The patient also complained of chest pain related to 
the CABG incision site and chest tube. He denied any cough 
or rhinorrhea and reported an improvement in dyspnea on 
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abstRaCt
INtRODUCtION: Amiodarone is often used in the suppression of tachyarrhythmias. One of the more serious adverse effects includes amiodarone 
pulmonary toxicity (APT). Several pulmonary diseases can manifest including interstitial pneumonitis, organizing pneumonia, acute respiratory distress 
syndrome, diffuse alveolar hemorrhage, pulmonary nodules or masses, and pleural effusion. Incidence of APT varies from 5–15% and is correlated to 
dosage, age of the patient, and preexisting lung disease.
DEsCRIPtION: A 56-year-old male with a past medical history of coronary artery disease and chronic obstructive pulmonary disease was admitted for 
a coronary artery bypass graft. Post-operatively, the patient was admitted to the ICU for ventilator management and continued to receive his home dose 
of amiodarone 400 mg orally twice daily, which he had been taking for the past 3 months. The patient was found to be hypoxemic with a PaO2 52 mmHg 
and bilateral infiltrates on chest x-ray. Patient also complained of new onset dyspnea. Physical exam found bilateral rhonchi with bibasilar crackles and 
subcutaneous emphysema along the left anterior chest wall. Daily chest x-rays showed worsening of bilateral interstitial infiltrates and pleural effusions. 
A chest high-resolution computed tomography on post-operative day 3 showed extensive and severe bilateral ground glass opacities. APT was suspected 
and amiodarone was discontinued. A course of oral prednisone without antibiotics was initiated, and after one week of treatment the chest film cleared, the 
PaO2 value normalized and dyspnea resolved.
DIsCUssION: APT occurs via cytotoxic T cells and indirectly by immunological reaction. Typically the lungs manifest a diffuse interstitial pneumonitis 
with varying degrees of fibrosis. Infiltrates with a ‘ground-glass’ appearance appreciated on HRCT are more definitive than chest x-ray. Pulmonary nodules 
can be seen, frequently in the upper lobes. These are postulated to be accumulations of amiodarone in areas of previous inflammation. Those undergoing 
major cardiothoracic surgery are known to be predisposed to APT. Some elements require consideration: a baseline pulmonary function test (PFT) did not 
exist prior. APT would manifest a restrictive pattern of PFTs. In APT diffusing capacity (DLCO) is generally .20 percent from baseline. A DLCO was 
not done in this patient. Therefore, not every type of interstitial lung disease could be ruled out. Key features support a clinical diagnosis: (1) new dyspnea, 
(2) exclusion of lung infection, (3) exclusion of heart failure, (4) new radiographic features, (5) improvement with withdrawal of amiodarone. Our case 
illustrates consideration of APT in patients who have extensive use of amiodarone and new onset dyspnea.
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high-flow oxygen. Other relevant medical history included 
peripheral vascular disease, dyslipidemia, and type II diabe-
tes mellitus (A1c 9.2). Home medications included aspirin, 
clopidogrel, atorvastatin, amiodarone, and ropinirole. Body 
mass index (kg/m2) was 26. He underwent a femoral popliteal 
bypass graft surgery in 2010 with a redo bypass in 2011. The 
patient has 44 pack-year history of cigarette smoking without 
history of alcohol or recreational drug abuse.
Upon physical examination, the patient was found to be 
febrile to 38.4 °C and normotensive with a pulse oximetry 
of 94% on high-flow nasal cannula. The cardiac examina-
tion revealed a regular rate and rhythm with normal heart 
sounds, and the pulmonary examination was notable for 
bilateral rhonchi and bibasilar crackles with normal Anterior-
poster (AP) diameter. He had a chest tube present anteriorly 
located below the xiphoid process. Subcutaneous emphysema 
was noted along the anterior left chest wall. A midline inci-
sion was also present at the site of the CABG. The dressing 
was clean, dry, and intact. Examination of the extremities 
showed no peripheral edema, with minimal venous stasis 
changes noted on the lower extremities. The remainder of 
the examination was unremarkable.
Upon review of the laboratory findings, he was noted to 
have a PaO2 of 52 mmHg. Daily portable CXRs demonstrated 
worsening of his bilateral interstitial infiltrates and pleural 
effusions. A high-resolution chest CT was obtained on post-
operative day 3, which showed extensive and severe bilateral 
ground glass opacities. The differential diagnosis considered 
at the time included pneumonia, acute decompensated heart 
failure, or COPD exacerbation. He did have leukocytosis with 
left shift but without bandemia; this was thought to be due to 
administration of IV steroids for suspected COPD exacerba-
tion and reactive response to stress from the CABG proce-
dure. An adequate sputum sample could not be obtained for 
culture. There was a suspicion of APT as a contributing factor 
of his new-onset dyspnea based on the imaging and clinical 
features. A Naranjo Scale score of six was assessed, sugges-
tive of probable APT. Amiodarone was discontinued, and 
he was started on oral prednisone without antibiotics. One 
week after initiation of the treatment, CXR of the patient 
demonstrated resolution of the bilateral interstitial infiltrates 
and pleural effusions. The PaO2 on ABG normalized, and his 
dyspnea resolved.
Discussion
Amiodarone is an antiarrhythmic agent often used to manage 
supraventricular and ventricular arrhythmias.1 It is an iodi-
nated benzofuran compound, which has a high affinity for sev-
eral organs including the lung tissue. It has a large side effect 
profile with APT being one of the most life-threatening side 
effects. Risk factors for developing APT include a high cumu-
lative dose (.400 mg/day), a duration of therapy exceeding 
two months, increased patient age, preexisting lung disease, 
thoracic or nonthoracic surgery, and pulmonary angiography.1 
The highest risk appears to occur in patients with abnormally 
low pretreatment pulmonary diffusing capacity of the lungs 
for carbon monoxide (DLCO) values.
The pathogenesis of APT is not completely understood. It 
has been implicated that a direct toxic injury to type II pneu-
mocytes and lung parenchyma and an indirect immunologic 
reaction in genetically predisposed patients are the two major 
mechanisms of action.5 Different forms of pulmonary disease, 
including interstitial pneumonitis, organizing pneumonia, 
acute respiratory distress syndrome, diffuse alveolar hemor-
rhage, pulmonary nodules and solitary masses, and pleural 
effusion, can occur due to amiodarone.1 Typically, the lungs 
manifest a diffuse interstitial pneumonitis with varying 
degrees of fibrosis. As shown in Figure 1, infiltrates with a 
ground glass appearance can be detected on high-resolution 
computed tomography (HRCT) in our patient, along with 
septal thickening, honeycombing, traction bronchiectasis, and 
pulmonary nodules.1,6,7 These nodules are frequently located 
in the upper lobes, which have been postulated to be accu-
mulations of amiodarone in areas of previous inflammation. 
HRCT can also demonstrate bilateral, asymmetric, hyper-
dense changes in the lungs and also in the liver and spleen 
due to the accumulation of the iodinated drug within mac-
rophages.6 HRCT is a more definitive imaging modality than 
a chest radiograph, which can show multiple, peripheral areas 
of dense airspace opacities, characterized as focal or diffuse 
reticular or ground glass.8
Pathology is the gold standard for diagnosing APT; how-
ever, a lung biopsy is not necessary in every patient.9,10 The his-
topathologic findings of APT include lipid laden macrophages 
in airspaces, nonspecific interstitial pneumonitis, type II 
pneumocyte hyperplasia, interstitial edema, and fibrosis.11
Figure 1. hRCt showing extensive and severe bilateral ground glass 
opacities. There is mild pleural thickening seen within the major fissures 
bilaterally and scattered lucencies seen within the chest wall extending to 
the bilateral axilla.
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Pulmonary function tests (PFTs) typically show a 
restrictive pattern with reduced forced vital capacity and 
total lung capacity (approximately $15% from baseline) in 
addition to a reduced diffusing capacity (DLCO; generally 
.20% decrease from baseline).9 For our patient, a base-
line PFT did not exist prior and a DLCO was not done. 
Therefore, not every type of interstitial lung disease (ILD) 
could be ruled out, and our differential for our patient 
accordingly included lung damage due to occupational or 
environmental agents, other drug-induced pulmonary tox-
icities, radiation-induced lung injury, and idiopathic causes. 
Occupational or environmental agents were less likely to be 
involved in the pathogenesis of our patient’s lung disease as 
he was not found to be exposed to known dusts, gases, or 
chemicals.12 A thorough history of the patient’s past medica-
tion use and radiation exposure is less likely to be a factor 
as he had not been exposed to other known drugs found to 
be a cause of ILD and had not been previously treated with 
therapeutic irradiation.13–15 A review of systems consistent 
with polymyositis/dermatomyositis, rheumatoid arthritis, 
systemic lupus erythematosus, scleroderma, and mixed con-
nective tissue disease was negative. The patient denied any 
family history of systemic diseases and inherited disease asso-
ciated with ILD, such as tuberous sclerosis, neurofibromato-
sis, familial hypocalciuric hypercalcemia, Hermansky–Pudlak 
syndrome, or Gaucher’s disease (Fig. 2).16
In addition to the understanding that those undergoing 
major cardiothoracic surgery are predisposed to APT, the fol-
lowing key features in our patient support a clinical diagnosis: 
(1) new-onset dyspnea, (2) new radiographic features, 
(3) improvement with withdrawal of amiodarone, (4) exclusion 
of lung infection, and (5) exclusion of heart failure.10 The sud-
den onset of a nonproductive cough and dyspnea tends to occur 
within 6–12 months of starting amiodarone, which is also 
characteristic of APT.10 Other presenting symptoms include 
fever, weight loss, pleuritic chest pain, and lethargy. There is no 
single diagnostic test pathognomonic for APT, and diagnosis 
is often one of exclusion and is made by the presence of a con-
stellation of clinical, laboratory, and radiographic findings. Our 
case illustrates consideration of APT in patients who have had 
extensive use of amiodarone and new-onset dyspnea following a 
cardiac procedure.
Conclusion
Amiodarone toxicity should be considered in patients who 
have extensive use of amiodarone with progressive or acute 
respiratory symptoms. It is relevant to remember that those 
patients with preexisting lung disease, those who use supple-
mental oxygen therapy, and those who are postcardiac sur-
gery patients all require evaluation for APT. Baseline chest 
radiograph and PFTs should be obtained prior to initiation of 
amiodarone.10,17 APT is a diagnosis of exclusion and is made 
on the basis of clinical, laboratory, and radiographic find-
ings. Prompt discontinuation of the drug and early aggressive 
corticosteroid therapy should be initiated once the diagnosis 
is determined.10
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Figure 2. how to sort between various forms of diffuse parenchymal lung disease.
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abbreviations
AP: anterior-posterior
APT: amiodarone pulmonary toxicity
CABG: coronary artery bypass graft
COPD: chronic obstructive pulmonary disease
CXR: chest X-ray
DLCO: diffusing capacity of the lungs for carbon monoxide
HRCT: high-resolution computed tomography
ILD: interstitial lung disease
PFT: pulmonary function test.
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supplementary table 1. Recent cases that describe ami-
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